Starpharma Holdings Limited (ASX:SPL, OCTQX:SPHRY) has inked a cancer drug agreement with global pharmaceutical company AstraZeneca.
The biotechnology company says the deal will give AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.
The identity of the anti-cancer molecules to be studied is covered by confidentiality restrictions.
Starpharma says the primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.
Starpharma Holdings reported a net loss of almost $14 million in the 2012 financial year.
